Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INO 8000

Drug Profile

INO 8000

Alternative Names: GLS-6150; Hepatitis C vaccine - Inovio/VGX; INO-8000; VGX-6150

Latest Information Update: 28 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Pennsylvania
  • Developer GeneOne Life Science; Inovio Pharmaceuticals; Mayo Clinic
  • Class DNA vaccines; Hepatitis C vaccines
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Hepatitis C

Most Recent Events

  • 28 Aug 2019 No recent reports of development identified for phase-I development in Hepatitis-C in Puerto Rico (IM, Injection)
  • 28 Jul 2019 No recent reports of development identified for phase-I development in Hepatitis-C in USA (IM, Injection)
  • 04 Sep 2018 Phase-I clinical trials in Hepatitis C (Prevention, Treatment-experienced) in South Korea (Intradermal) before September 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top